...
首页> 外文期刊>Hepato-gastroenterology. >Clinicopathologic Significance in Serum Presence of Anti-p53 Antibody in Patients with Colorectal Carcinoma
【24h】

Clinicopathologic Significance in Serum Presence of Anti-p53 Antibody in Patients with Colorectal Carcinoma

机译:大肠癌患者血清中抗p53抗体的临床病理学意义

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: Alteration of p53 gene links to the appearance and detection of anti-p53 antibodies in the serum. The aim of this study is to find the clinicopathologic significance for serum presence of anti-p53 antibodies in patients with colorectal carcinoma. Methodology: Serum presence of anti-p53 antibodies was examined for sera of 36 patients with colorectal carcinoma using enzyme-linked immunosor-bent assay.Results: Frequency of serum presence of anti-p53 antibodies was 47.2% (17 of 36). Incidence of lymph node metastasis and lymphatic invasion in tumors coexisting with serum presence of anti-p53 antibodies (70.6%, 12 of 17 and 94.1%, 16 of 17) were signif-icantly higher than those in tumors without serum presence of anti-p53 antibodies (17.6%, 3 of 17 and 68.4%, 13 of 19;p=0.007 and p=0.041, respectively). Stages of the tumors were significantly more advanced in carcinomas coexisting with serum presence of anti-p53 antibodies (p=0.023). Frequency in serum presence of anti-p53 antibodies among patients with tumors expressing p53 (73.7%, 14 of 19) was significantly higher than that among patients with tumors without p53 expression (17.6%, 3 of l7;p=0.0005).Conclusions: Preoperative serum appearance of anti-53 antibodies can be an indicator for more malignant potential of colorectal carcinoma.
机译:背景/目的:p53基因的改变与血清中抗p53抗体的出现和检测有关。这项研究的目的是发现大肠癌患者血清中抗p53抗体的临床病理意义。方法:采用酶联免疫吸附试验检测了36例结直肠癌患者的血清中是否存在抗p53抗体。结果:抗p53抗体的血清存在率为47.2%(36分中的17分)。与血清中存在抗p53抗体并存的肿瘤中的淋巴结转移和淋巴管浸润的发生率(70.6%,17中的12和94.1%,16中的16)显着高于无血清中存在抗p53抗体的肿瘤抗体(分别为17.6%,17个中的3个和68.4%,19个中的13个; p = 0.007和p = 0.041)。在与抗p53抗体的血清共存的癌中,肿瘤的分期明显更晚期(p = 0.023)。表达p53的肿瘤患者中抗p53抗体的血清出现频率(73.7%,19 of 14)明显高于未表达p53的肿瘤患者(17.6%,3 of 7; p = 0.0005)。术前血清抗53抗体的出现可能是大肠癌潜在恶性程度的指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号